綠葉製藥阿卡波糖膠囊（貝希）通過一致性評價，有效保障患者用藥需求

By PR Newswire on 04 Jun 2019

PR Newswire (www.prnasia.com), a Cision company, is the premier global provider of media monitoring platforms and news distribution services that marketers, corporate communicators and investor relations professionals leverage to engage key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, distribute, target and measure text and multimedia content across traditional, digital, mobile and social channels. Combining the world's largest multi-channel content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and Asia-Pacific regions.

北京2019年6月4日 /美通社/ -- 綠葉製藥集團宣佈，其治療糖尿病的核心產品「阿卡波糖膠囊」（商品名：貝希）已獲國家藥品監督管理局批准，通過仿製藥質量和療效一致性評價。本次通過一致性評價，證明貝希與原研藥的質量和療效一致，可實現臨床相互替代，有效保障更多患者的用藥需求。

中國是糖尿病第一大國，患者群體高達約1.14億人。流行病學調查顯示，我國80%以上糖尿病患者表現為餐後高血糖。新診斷的糖尿病患者中，單純餐後血糖升高者占近50%。在所有降糖藥物中，阿卡波糖控制餐後血糖優勢突出，適合中國人的飲食習慣，已成為我國應用最廣泛，臨床獲益證據最充分的口服降糖藥之一。2018年，中國阿卡波糖產品的市場總值估計約為人民幣100億元。